RT Book, Section A1 Ijioma, Nkechinyere A1 Gulati, Martha A2 Gulati, Martha SR Print(0) ID 1128088252 T1 INTRODUCTION T2 Color Atlas and Synopsis of Women's Cardiovascular Health YR 2016 FD 2016 PB McGraw-Hill Education PP New York, NY SN 9780071786201 LK accesscardiology.mhmedical.com/content.aspx?aid=1128088252 RD 2024/03/29 AB Cardiovascular disease (CVD) is the leading cause of death in women. For more than 2 decades, more women have died from CVD compared to men.1 However, for several decades, CVD was regarded as a male disease. Women were underrepresented in cardiovascular clinical trials and comprised <27% of trial participants.2 Only 33% of clinical trials reported sex-specific outcomes.2 These low enrolment numbers resulted in most clinical trials being underpowered to evaluate for gender-specific outcomes. This has had significant implications because for carrying out clinical translation of research in a specific population group, that population group should adequately represented in research study. This has not been the case for women in most major cardiovascular trials. Moreover, a growing body of evidence has suggested that there may be differences in the clinical presentation of CVDs in men and women, in addition to sex differences in terms of impact of cardiovascular risk factors, CVD prevention, and even the pathophysiology of CVD.